News for Healthier Living

Trial Assesses Antibody Therapy for Chronic Active Antibody-Mediated Kidney Transplant Rejection

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients' kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23- 27.

October 26, 2024


October 31 2024

October 30 2024

October 29 2024

October 28 2024

October 27 2024

October 26 2024

October 25 2024

October 24 2024

October 23 2024

October 22 2024

October 21 2024

October 20 2024

October 19 2024

October 18 2024

October 17 2024